Related Experiment Video
Updated: Sep 27, 2026

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
Published on: September 17, 2014
From Fabrication to Function: Scalable Spray-Assisted Layer-by-Layer Films for Drug Delivery in Glaucoma
Alexandra M L Oliveira1,2, Maria Raposo3, Sorawee Yanwinitchai4
1NOVA Medical School, Faculdade de Ciências Médicas (NMS, FCM), Universidade Nova de Lisboa, 1160-056 Lisboa, Portugal.
Abstract:
Glaucoma drainage device (GDD) surgery is frequently limited by postoperative fibroblast proliferation, leading to device failure and the need for revision procedures. In this work, we developed a spray-assisted layer-by-layer (LbL) drug delivery system for GDD surfaces intended to enable localized release of antiproliferative agents, as a proof-of-concept approach toward more standardized patient care. Multilayer thin films composed of poly(β-amino ester) (PBAE) and a 5-fluorouracil (5-FU) and β-cyclodextrin (β-CD) complex (5-FU:β-CD) were fabricated, without (type A films) and with (type B films) graphene oxide (GO) barrier layers. Film growth was monitored by ultraviolet-visible spectroscopy (UV-Vis) and vacuum ultraviolet spectroscopy (VUV), confirming consistent, sequential deposition; type A films exhibited lower variability than GO-containing type B films. Drug release studies revealed a rapid burst release within the first 5 min, followed by a plateau, regardless of GO incorporation, indicating that sustained drug release was not achieved under the current film architecture. Cell cycle analysis confirmed that β-CD complexation preserved the biological activity of 5-FU, which induced an S-phase arrest in a dose-dependent manner. Although further optimization of film architecture and composition is required to improve release control and achieve sustained delivery, this study demonstrates the feasibility of spray-assisted LbL coatings as a localized drug delivery strategy for GDD surfaces. Overall, these findings support the proof-of-concept nature of this approach and identify key parameters that must be optimized before translational applicability can be established.
Related Concept Videos
Ophthalmic Drug Delivery Systems
Modified-Release Drug Delivery Systems: Rate-Programmed II

